ICT

ICT Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapies for both hematological malignancies and solid tumors. The company's proprietary Coupled-CAR platform is designed to enhance the expansion and persistence of CAR-T cells within the immunosuppressive microenvironment of solid tumors, a significant challenge for traditional cell therapies. Their lead programs target well-validated antigens such as CD19 and BCMA, while their innovative pipeline extends to difficult-to-treat indications like glioblastoma and mesothelin-expressing cancers. By leveraging advanced genetic engineering, ICT Therapeutics aims to provide more durable and effective treatment options for patients with advanced cancers.